Bone turnover markers in clinical practice

2002 ◽  
pp. 99-114
Author(s):  
Richard Eastell ◽  
Sheila Hart
Keyword(s):  
Clinical Practice ◽  
Bone Turnover ◽  
Bone Turnover Markers ◽  
Turnover Markers

scholarly journals DIAGNOSIS OF ENDOCRINE DISEASE: Bone turnover markers: are they clinically useful?

2018 ◽  
Vol 178 (1) ◽  
pp. R19-R31 ◽  
Author(s):  
Richard Eastell ◽  
Tom Pigott ◽  
Fatma Gossiel ◽  
Kim E Naylor ◽  
Jennifer S Walsh ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Bone Turnover ◽  
Bone Turnover Markers ◽  
Reference Interval ◽  
Endocrine Disease ◽  
A Value ◽  
Anabolic Treatment ◽  
Clinical Practice Setting ◽  
Anabolic Therapy ◽  
Turnover Markers

Bone turnover markers (BTMs) are useful in clinical practice as they are inexpensive, and they have proven useful for treatment monitoring and identification of poor adherence. BTMs cannot be used in individual patients for identifying accelerated bone loss or an increase in fracture risk or in deciding on the optimal therapy. They are useful for monitoring both anti-resorptive and anabolic treatment. Response can be defined as a result that exceeds an absolute target, or by a change greater than the least significant change; if such a response is not present, then poor compliance or secondary osteoporosis are likely causes. A baseline BTM measurement is not always made; in that case, a value of BTM on anti-resorptive treatment that is low or low normal or above the reference interval for anabolic therapy may be taken to indicate a satisfactory response. We provide an approach to using these bone turnover markers in clinical practice by describing algorithms for anti-resorptive and anabolic therapy and describing the changes we observe in the clinical practice setting.

Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney Disease

2019 ◽  
Vol 49 (4) ◽  
pp. 284-293 ◽  
Author(s):  
Stephen A. Strugnell ◽  
Stuart M. Sprague ◽  
Akhtar Ashfaq ◽  
Martin Petkovich ◽  
Charles W. Bishop
Keyword(s):  
Chronic Kidney Disease ◽  
Vitamin D ◽  
Clinical Practice ◽  
Bone Turnover ◽  
Bone Turnover Markers ◽  
Hydroxyvitamin D ◽  
Calcium Phosphorus ◽  
Safety Parameters ◽  
25 Hydroxyvitamin D ◽  
Turnover Markers

Background: Vitamin D repletion is recommended for secondary hyperparathyroidism (SHPT) and associated vitamin D insufficiency (VDI) in chronic kidney disease (CKD), but optimal levels of serum total 25-hydroxyvitamin D remain undefined. Clinical practice guidelines target sufficiency, whereas recent data indicate that higher levels are required to control the elevation of intact parathyroid hormone (iPTH) as CKD advances. This secondary analysis of 2 randomized controlled trials seeks to identify the minimum level of mean serum 25-hydroxyvitamin D required to control SHPT arising from VDI in stage 3 or 4 CKD. Methods: Adult subjects (n = 429) with SHPT, VDI, and stage 3 or 4 CKD were stratified by stage and treated daily with either extended-release calcifediol (ERC) or placebo in 2 identical, parallel, randomized, double-blind studies. After treatment for 26 weeks, all subjects were ranked by the level of serum total 25-hydroxyvitamin D and divided into quintiles in order to examine the relationships between the degree of vitamin D repletion and the associated changes in plasma iPTH, serum bone turnover markers, calcium, phosphorus, intact fibroblast growth factor 23 (FGF23) and vitamin D metabolites, estimated glomerular filtration rate (eGFR), and urine calcium:creatinine (Ca:Cr) ratio. Results: Progressive increases in serum 1,25-dihydroxyvitamin D and reductions in plasma iPTH and serum bone turnover markers were observed as mean posttreatment serum 25-hydroxyvitamin D rose from 13.9 ng/mL (in Quintile 1) to 92.5 ng/mL (in Quintile 5), irrespective of CKD stage. Mean serum calcium, phosphorus and FGF23, eGFR, and urine Ca:Cr ratio (collectively “safety parameters”) did not significantly change from Quintile 1. Suppression of iPTH and bone turnover markers was not observed until serum 25-hydroxyvitamin D rose to at least 50.8 ng/mL (Quintile 3). Conclusion: ERC therapy produced exposure-dependent reductions in plasma iPTH and bone turnover markers only when mean serum total 25-hydroxyvitamin D reached at least 50.8 ng/mL, indicating that current targets for vitamin D repletion therapy in CKD are too low. Gradual elevation of mean serum 25-hydroxyvitamin D to 92.5 ng/mL was not associated with significant adverse changes in safety parameters.

Bone turnover markers: understanding their value in clinical trials and clinical practice

2009 ◽  
Vol 20 (6) ◽  
pp. 843-851 ◽  
Author(s):  
R. Civitelli ◽  
R. Armamento-Villareal ◽  
N. Napoli
Keyword(s):  
Clinical Trials ◽  
Clinical Practice ◽  
Bone Turnover ◽  
Bone Turnover Markers ◽  
Turnover Markers

Use of bone turnover markers in clinical practice

2012 ◽  
Vol 19 (6) ◽  
pp. 468-473 ◽  
Author(s):  
Emmanuel Biver
Keyword(s):  
Clinical Practice ◽  
Bone Turnover ◽  
Bone Turnover Markers ◽  
Turnover Markers

scholarly journals Use of Bone Turnover Markers in Clinical Practice for the Management of Osteoporosis in Korea: From the Survey on the Prescription Pattern of Bone Turnover Markers

2019 ◽  
Vol 26 (4) ◽  
pp. 271 ◽  
Author(s):  
Seong Hee Ahn ◽  
So Young Park ◽  
Jun-Il Yoo ◽  
Youn-Jee Chung ◽  
Yun Kyung Jeon ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Bone Turnover ◽  
Bone Turnover Markers ◽  
Prescription Pattern ◽  
Turnover Markers

Alendronate daily, weekly in conventional tablets and weekly in enteric tablets: preliminary study on the effects in bone turnover markers and incidence of side effects

2003 ◽  
Vol 23 (3) ◽  
pp. 278-281
Author(s):  
J. E. Blümel ◽  
C. Castelo-Branco ◽  
G. De La Cuadra ◽  
L. Maciver ◽  
M. Moreno ◽  
...  
Keyword(s):  
Side Effects ◽  
Bone Turnover ◽  
Bone Turnover Markers ◽  
Preliminary Study ◽  
Turnover Markers

Age-dependent effects of atorvastatin on biochemical bone turnover markers: a randomized controlled trial in postmenopausal women

2004 ◽  
Vol 112 (S 1) ◽  
Author(s):  
I Berthold ◽  
S Unverdorben ◽  
A Zittermann ◽  
R Degenhardt ◽  
H Vetter ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Bone Turnover ◽  
Postmenopausal Women ◽  
Bone Turnover Markers ◽  
Controlled Trial ◽  
Randomized Controlled ◽  
Age Dependent ◽  
Turnover Markers

Bone mineralization density distribution, bone formation rate and bone turnover markers in a cohort of children with CKD before and after GH treatment

2013 ◽  
Author(s):  
Fratzl-Zelman Nadja ◽  
Nawrot-Wawrzyniak Kamilla ◽  
Misof Barbara ◽  
Panczyk-Tomaszewska Malgorzata ◽  
Ziolkowska Helena ◽  
...  
Keyword(s):  
Bone Formation ◽  
Bone Turnover ◽  
Density Distribution ◽  
Bone Turnover Markers ◽  
Bone Mineralization ◽  
Formation Rate ◽  
Gh Treatment ◽  
Bone Formation Rate ◽  
Before And After ◽  
Turnover Markers
Sign in / Sign up

Export Citation Format

Share Document